Kemstro is a drug owned by Ucb Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 09, 2018. Details of Kemstro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6024981 | Rapidly dissolving robust dosage form |
Apr, 2018
(8 years ago) |
Expired
|
| US6221392 | Rapidly dissolving robust dosage form |
Apr, 2018
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Kemstro is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Kemstro's family patents as well as insights into
ongoing legal events
on those patents.
Kemstro's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Kemstro:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Kemstro's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 09, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kemstro Generic API suppliers:
Baclofen is the generic name for the brand Kemstro. 32 different companies have already filed for the generic of Kemstro, with Rubicon Research having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Kemstro's generic
Alternative Brands for Kemstro
There are several other brand drugs using the same active ingredient (Baclofen) as Kemstro. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Baclofen, Kemstro's active ingredient. Check the complete list of approved generic manufacturers for Kemstro
About Kemstro
Kemstro is a drug owned by Ucb Inc. Kemstro uses Baclofen as an active ingredient. Kemstro was launched by Ucb in 2003.
Approval Date:
Kemstro was approved by FDA for market use on 30 October, 2003.
Active Ingredient:
Kemstro uses Baclofen as the active ingredient. Check out other Drugs and Companies using Baclofen ingredient
Dosage:
Kemstro is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |